named patient
Unlicensed Medicines – the Pharmacovigilance Impact!
The COVID-19 situation made it possible for regulatory agencies globally to explore all the four facets of unlicensed medicines, namely: 1. Emergency Use Authorization 2. Compassionate Use 3. Named Patient Basis 4. Expanded Access Program The first and foremost thing to understand is that the medicine in question can fall into any of the following […]